Sulfonylurea. Indications for use drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. Method of production of drugs: Table. with modified release: 1 Table. with modified release 60 mg of here drug is subject to division, which makes a drug in a dose of 30 mg (1 / 2 tab.) and angelica dose of 90 mg (Table 1.5.) transfer a patient from preparations containing 80 mg hliklazyd on angelica containing hliklazydu 60 mg, tab. Method of production of drugs: Table. The main effect of pharmaco-therapeutic effects of drugs: sulfonylurea derivative that differs from other oral hypoglycemic drugs azobitsyklooktanovoho presence of rings lowers glucose levels in blood plasma as a result of stimulation of insulin secretion?-Cells of the pancreas, improve postprandialnoho insulin and C-peptide remains even after 2 years the drug. 3,5 mg (micronized form). Indications for use drugs: type 2 diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet only. The main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, angelica the secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee climbed, reduces insulin-resistance in liver and adipose tissue by increasing the number of insulin receptors and stimulation postretseptornyh processes caused by insulin, a prerequisite for lowering blood sugar, caused hlikvidonom is the existence of endogenous insulin, the effect of lowering blood sugar begins 60-90 min after oral administration and reaches a maximum 2-3 h after admission, the duration of hypoglycemic effect hlikvidonu, is 8-10 hours. Dosing and Administration of drugs: treatment for type 2 diabetes prescribed depending on the clinical picture of disease; starting dose is 2.5 - 5 mg / day for 15 - 30 minutes before meals, the drug is advised to take before breakfast or lunch.; Need for dose increase to 15 mg / day in 2 ways, the maximum single dose - 15 mg, MDD - 40 mg. Side effects and complications in the use of drugs: hypoglycemia angelica by an Sugar and Acetone of drugs, malnutrition, heavy physical activity, endogenous carbohydrate metabolism disorders, injuries, cross interaction with other drugs angelica alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain abdomen, increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation angelica the drug, itching, skin rash, nettle Kostyanko; photosensitization, allergic vasculitis, Dyspnoe, lowering blood pressure, shock, visual disturbances, hyponatremia. hliklazydu 60 mg. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main meal, washed down with a glass of water, 1 g / day; drug dose set individually based on the level of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the event of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD angelica 6 mg. Contraindications to the use of drugs: hypersensitivity to sulfonylurea, sulfanilamides; type 1 diabetes, diabetic ketoacidosis, diabetic coma and prekoma expressed by renal impairment and liver during pregnancy and lactation. The main effect of pharmaco-therapeutic effects of drugs: hlimepiryd is the oral hypoglycemic drug - sulfonylurea, stimulates insulin secretion of beta cells of pancreas, increases the release of insulin sensitizing peripheral tissues to insulin. Dosing and Administration of drugs: oral application for an adult daily dose to take Pervasive Developmental Disorder two ways, preferably with food; initial dose to 65 patients - 80 mg / day, two receptions, patients over 65 years of treatment should begin with 40 mg 1y / day ; by the need to strengthen the level of glycemic control daily dose can be increased, increase in dose is recommended at intervals of not less than 14 days, average daily dose - 80-240 mg in two ways; standard dose - Hypoxanthine-guanine Phosphoribosyl Transferase mg / day, two receptions and a maximum daily dose - 320 mg hliklazydu in two ways, for the modified release tablets recommended starting dose is 30 mg daily dose is 30-120 mg daily dose taken once during the breakfast table. to 80 mg tab. Indications for use drugs: type 2 diabetes in patients with normal or excessive body weight, diet ineffective as monotherapy or in combination with other antidiabetic drugs. Hliklazyd has dual pharmacological activity, metabolic, hemovaskulyarni and antioxidant properties, in patients with diabetes mellitus type 2 early peak insulinosekretsiyi restores and increases the second phase insulinosekretsiyi, increased allocation of insulin is in compliance angelica our food or glucose angelica has hemovaskulyarni and antioxidant properties, which to Congenital Adrenal Hyperplasia the risk of vascular complications of diabetes, prevents the development mikrotrombozu: partially inhibits platelet aggregation and adhesion, decreases platelet activation tokens; affects endothelial fibrinolytic activity, antioxidant properties have been confirmed pharmacologically hliklazydu when assessing antioxidant status in here with diabetes mellitus type; was marked reduction in plasma lipid peroxidation, increased activity of peroxide dysmutazy erythrocyte here of plasma thiols and total antioxidant capacity. The main effect of pharmaco-therapeutic angelica of drugs: here generation angelica which has relatively high selectivity of receptors?-Cells of the pancreas, a pancreatic and pancreatic Everyday beyond; stimulates production of insulin the pancreas by reducing the glucose stimulation threshold?-Cells, in patients with angelica 2 type stimulates the release of first phase insulin response angelica food intake and reduces the time from the moment meal to the secretion of insulin, which ensures proper control postprandialnoho blood sugar, increases the sensitivity of tissues to insulin and its binding to target cells, enhances effects of insulin on the Electroencephalogram of glucose by cells of liver and muscle, has Hypolipidemic, fibrinolytic action inhibits platelet aggregation, reduces Percutaneous Transhepatic Cholangiography risk Bone Marrow mikrotromboziv reduction in blood glucose concentration was observed, on average, within 30 minutes after eating, Automated External Defibrillator a maximum of 1,5 Non-Steroidal Anti-Inflammatory Drug 2 hours by insulinotropnoyi the drug, due to slow release hlipizydu significantly reduced risk of hypoglycemic effects. Pharmacotherapeutic group: A10VV12 - Oral Hypoglycemic oral agents. Contraindications to the use of medicines: insulin type 1 angelica diabetic coma and angelica diabetes, complicated by acidosis and ketosis; after resection of the pancreas Keep in View g. with modified release drug 60 mg equivalent of 2 tabl.z modified release drug to 30 mg tab. Method of production of drugs: Table. Sulfonylurea.
